Press Releases :: VolitionRx Ltd (VNRX)

Jul 19, 2017 4:30 pm EDT

VolitionRx Limited to host a conference call regarding a 13,500 Subject Colorectal Cancer Screening Trial with the Early Detection Research Network of the U.S. National Cancer Institute

Jul 18, 2017 6:30 am EDT

Volition America, Inc. Announces a Colorectal Cancer Screening Trial containing approximately 13,500 Subjects in Collaboration with the Early Detection Research Network of the U.S. National Cancer Institute

Jun 30, 2017 9:22 am EDT

Volition to Present at the EuropaColon Advocacy Masterclass and Exhibit at the European Society for Medical Oncology Gastrointestinal Cancer Congress

Jun 27, 2017 7:30 am EDT

VolitionRx Limited Corrects an Earlier Announcement

May 26, 2017 6:30 am EDT

VolitionRx Limited to Present at Multiple Investor Conferences in June

May 18, 2017 9:00 am EDT

A new publication reports that 91% of colorectal cancers were detected at 90% specificity in a completed prospective trial using Volition's Nu.Q(TM) assays

May 11, 2017 6:30 am EDT

VolitionRx Limited Announces First Quarter 2017 Financial Results and Business Update

May 8, 2017 8:00 am EDT

VolitionRx Limited Schedules First Quarter 2017 Earnings Conference Call and Business Update

Apr 27, 2017 7:46 am EDT

Volition makes progress with its Colorectal Cancer Screening Triage Test in both Asia and Europe

Apr 21, 2017 8:26 am EDT

Volition opens a new Research and Development facility in Belgium with a state of the art, purpose-built laboratory

rss_feed News RSS